Drug Trial Radar · NCT00927654
Iloprost in High Risk Cardiac Surgical Patients
Last checked: Nov 20, 2026Latest source record: Jan 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
253
Actual
Start
Jun 2009
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Ludwig-Maximilians - University of MunichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Algora
- First posted
- Jun 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study effects of the intra operative, prophylactic inhalation of Iloprost (Ventavis) before and during extracorporal circulation on perioperative morbidity and outcome in high risk cardiac surgical patients is investigated in comparison to placebo.
Conditions
- Pulmonary Hypertension
Interventions
Iloprost (Ventavis)Drug
Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
Isotonic Sodium Chloride solution 0.9 % (placebo)Drug
Twice at day 0 intraoperatively
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of post-operative artificial respiration after arrival on intensive care unitTime frame: 2-3 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital of the university of Aachen
Aachen, Germany
Herz- und Diabeteszentrum NRW
Bad Oeynhausen, Germany
Deutsches Herzzentrum Berlin
Berlin, Germany
Hospital of the university of Duesseldorf
Düsseldorf, Germany
Hospital of the university of Frankfurt
Frankfurt, Germany
Hospital of the university of munich
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.